Illumina (Nasdaq:ILMN) announced today that it launched a new research test, co-developed with Merck (NYSE:MRK). The jointly developed test adds the assessment of a new genomic signature to the already distributed TruSight Oncology 500 assay, enabling researchers to unlock deeper insights about the tumor genome by identifying genetic mutations used in the evaluation of homologous […]
Merck
Baxter, 3M, Abbott near the top of Newsweek’s most responsible companies list
Several medtech, healthcare and life sciences companies, including big names like Abbott (NYSE:ABT), 3M (NYSE:MMM) and Baxter (NYSE:BAX), are among the 500 “most responsible,” according to Newsweek. The outlet published its “America’s Most Responsible Companies 2022” list, marking the third installment of the compilation (in partnership with Statista), this time expanded to include 500 of […]
FDA advisory committee votes in favor of COVID-19 pill molnupiravir
FDA’s Antimicrobial Drugs Advisory Committee narrowly concluded that the benefits of Merck’s (NYSE:MRK) COVID-19 pill molnupiravir outweigh the risks. A total of 13 members of the panel voted in favor of the drug candidate, while 10 voted against it. There were no abstentions. Get the full story form our sister site, Drug Discovery & Development.
Why Public Citizen is skeptical about the COVID-19 antiviral molnupiravir
Dr. Michael Carome, director of Public Citizen’s health research group, is concerned about Merck’s SARS-CoV-2 antiviral molnupiravir. If it wins emergency use authorization (EUA), molnupiravir would be the first oral treatment for COVID-19. But Carome brought up several potential problems with molnupiravir during today’s public comment period of the FDA’s Antimicrobial Drugs Advisory Committee meeting. […]
Xeris enters collaboration with Merck
Xeris Biopharma (NSDQ:XERS) announced today that it entered into a collaboration agreement with Merck (NYSE:MRK) for its XeriJect technology. Chicago-based Xeris’ collaboration with Merck includes an option to license the XeriJect suspension-based formulation technology for use with undisclosed monoclonal antibodies (mAbs) for engineering ultra-high concentration, ready-to-use formulations. Get the full story at our sister site, Drug Delivery Business […]
Early safety concerns accompanied Merck’s molnupiravir, the first potential oral COVID-19 therapy
The antiviral molnupiravir appears to be destined to become the first oral treatment for COVID-19. Merck and its partner Ridgeback Biotherapeutics intend to file for emergency use authorization after announcing that the drug appears to reduce the risk of hospitalization or death by about 50%. One potential hurdle for the drug is whether unvaccinated individuals […]
Illumina, Merck partner on diagnostics for identifying specific cancer mutations
Illumina (NSDQ:ILMN) and Merck today announced a partnership to develop diagnostics for identifying certain genetic mutations. The partnership aims to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD), leveraging Illumina’s TruSight Oncology 500 (TSO 500) content, enabling what the companies tout as the most comprehensive genomic […]
MedTech 100 roundup: Industry climbs again
The medtech industry built off a strong performance two weeks ago with another uptick in the midst of an up-and-down year. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 18) at 110.64 points, producing a 0.9% rise from the 109.63-point mark set one week […]
Merck spinoff Organon completes Alydia Health acquisition
Merck (NYSE: MRK) spinoff Organon (NYSE:OGN) today announced the completion of its acquisition of Alydia Health for up to $240 million. Alydia Health develops treatments centered around preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. The company designed its Jada system to control and treat abnormal postpartum uterine […]
U.S. to buy nearly 2 million courses of Merck’s COVID-19 antiviral treatment
Merck (NYSE:MRK) announced today that it agreed to supply the U.S. government with its molnupiravir (MK-4482) for treating COVID-19. Molnupiravir, developed through a collaboration between Merck and Ridgeback Biotherapeutics, is currently under evaluation in a Phase 3 clinical trial for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 infection and at least one risk factor […]
10 of the best pharma companies to work for
The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research. The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries. To get a sense of which pharmaceutical companies […]
